Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by MetzGERon Jan 11, 2020 3:27pm
60 Views
Post# 30542627

RE:RE:RE:RE:RE:RE:RE:RE:RE:Share Price (Unbiased Opionion)

RE:RE:RE:RE:RE:RE:RE:RE:RE:Share Price (Unbiased Opionion)No I don’t think so.
i just wanted to Say that RepliCel knows how they promote RCI-02, RCS, RCT and further development
the Big problem and question is SHISEIDO. I have no problem to wait until the stock goes up and I get money.
but I have a problem if I loose hair every single day and there could have been a solution for me since 1 year and a business fight is the reason for becoming bald.
I have to repeat: RCH-01 is a maintenance treatment, maybe some regrowth. But more than 30% regrowth isn’t possible I think. A 40 year old bald man won’t be able to get his hair back.
and the „significant results“ which was shown in the RCS trial could mean everything.
in the phase 1 study of RCH-01 there was also mentioned „significant results“ but this was „only“ 11% average regrowth which is not significant in my opinion. If SHISEIDO waits another couple of months there will come other players to the market with possibility to regrowth a full head of hair (Kyocera) or developing 10.000 follicles out of 30 donor follicles (TissUse/J hewitt). If this is the case, RCH-01 would not be worth so much money. You have to think about that 
Bullboard Posts